These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Aβ-amyloid and Tau Imaging in Dementia. Villemagne VL; Doré V; Bourgeat P; Burnham SC; Laws S; Salvado O; Masters CL; Rowe CC Semin Nucl Med; 2017 Jan; 47(1):75-88. PubMed ID: 27987560 [TBL] [Abstract][Full Text] [Related]
6. Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease. Blennow K; Hampel H; Zetterberg H Neuropsychopharmacology; 2014 Jan; 39(1):189-201. PubMed ID: 23799530 [TBL] [Abstract][Full Text] [Related]
7. From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: the role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia. Pasinetti GM J Alzheimers Dis; 2002 Oct; 4(5):435-45. PubMed ID: 12446975 [TBL] [Abstract][Full Text] [Related]
8. Dementia screening, biomarkers and protein misfolding: Implications for public health and diagnosis. Galvin JE Prion; 2011; 5(1):16-21. PubMed ID: 21164279 [TBL] [Abstract][Full Text] [Related]
9. Computational Causal Modeling of the Dynamic Biomarker Cascade in Alzheimer's Disease. Petrella JR; Hao W; Rao A; Doraiswamy PM Comput Math Methods Med; 2019; 2019():6216530. PubMed ID: 30863455 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies. Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463 [TBL] [Abstract][Full Text] [Related]
11. Amyloid-beta immunotherapy: the hope for Alzheimer disease? Barrera-Ocampo A; Lopera F Colomb Med (Cali); 2016 Dec; 47(4):203-212. PubMed ID: 28293044 [TBL] [Abstract][Full Text] [Related]
12. Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial. Kokjohn TA; Roher AE CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):88-97. PubMed ID: 19355930 [TBL] [Abstract][Full Text] [Related]
13. Amyloid-beta immunotherapy for Alzheimer's disease. Fu HJ; Liu B; Frost JL; Lemere CA CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):197-206. PubMed ID: 20205640 [TBL] [Abstract][Full Text] [Related]
14. Disease-modifying therapies in Alzheimer's disease: how far have we come? Hüll M; Berger M; Heneka M Drugs; 2006; 66(16):2075-93. PubMed ID: 17112302 [TBL] [Abstract][Full Text] [Related]
15. Cognitive symptoms of Alzheimer's disease: clinical management and prevention. Joe E; Ringman JM BMJ; 2019 Dec; 367():l6217. PubMed ID: 31810978 [TBL] [Abstract][Full Text] [Related]
16. Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. Lemere CA; Maier M; Jiang L; Peng Y; Seabrook TJ Rejuvenation Res; 2006; 9(1):77-84. PubMed ID: 16608400 [TBL] [Abstract][Full Text] [Related]
17. Novel Therapeutic Strategies for Dementia. Cacabelos R; Torrellas C; Carrera I; Cacabelos P; Corzo L; Fernández-Novoa L; Tellado I; Carril JC; Aliev G CNS Neurol Disord Drug Targets; 2016; 15(2):141-241. PubMed ID: 26831267 [TBL] [Abstract][Full Text] [Related]
18. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ; Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505 [TBL] [Abstract][Full Text] [Related]
19. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging. Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773 [TBL] [Abstract][Full Text] [Related]
20. Blood biomarkers as surrogate endpoints of treatment responses to aerobic exercise and cognitive training (ACT) in amnestic mild cognitive impairment: the blood biomarkers study protocol of a randomized controlled trial (the ACT Trial). Li D; Mielke MM; Bell WR; Reilly C; Zhang L; Lin FV; Yu F Trials; 2020 Jan; 21(1):19. PubMed ID: 31907024 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]